Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 8
Submit an article Journal homepage
247
Views
4
CrossRef citations to date
0
Altmetric
Theme: Breast Cancer - Review

Ductal carcinoma in situ: an overview

Shivani Duggal National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, USA; Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, USA; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, USA; Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, USA
,
Julieta Robin Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, USA; Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, USA
&
Thomas B Julian National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, USA. [email protected]; Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, USA; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, USA. [email protected]; Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, USA
Pages 955-962 | Published online: 10 Jan 2014

References

  • Kerlikowske K. Epidemiology of ductal carcinoma in situ. J. Natl Cancer Inst. Monogr. 41, 139–141 (2010).
  • Skaane P, Hofvind S, Skjennald A. Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population-based screening program: follow-up and final results of Oslo II study. Radiology 244(3), 708–717 (2007).
  • Vigeland E, Klaasen H, Klingen TA, Hofvind S, Skaane P. Full-field digital mammography compared to screen film mammography in the prevalent round of a population-based screening programme: The Vestfold County Study. Eur. Radiol. 18(1), 183–191 (2008).
  • Karssemeijer N, Bluekens AM, Beijerinck D et al. Breast cancer screening results 5 years after introduction of digital mammography in a population-based screening program. Radiology 253(2), 353–358 (2009).
  • Domingo L, Romero A, Belvis F et al. Differences in radiological patterns, tumour characteristics and diagnostic precision between digital mammography and screen-film mammography in four breast cancer screening programmes in Spain. Eur. Radiol. 21(9), 2020–2028 (2011).
  • Bluekens AM, Holland R, Karssemeijer N, Broeders MJ, den Heeten GJ. Comparison of digital screening mammography and screen-film mammography in the early detection of clinically relevant cancers: a multicenter study. Radiology 265(3), 707–714 (2012).
  • Pisano ED, Yaffe MJ, Hemminger BM et al. Current status of full-field digital mammography. Acad. Radiol. 7, 266–280 (2000).
  • Pisano ED, Yaffe MJ. Digital mammography. Radiology 234, 353–361 (2005).
  • Gilles R, Guinebretière JM, Lucidarme O et al. Non-palpable breast tumors: diagnoses with contrast-enhanced subtraction dynamic MR imaging. Radiology 191, 625–631 (1994).
  • Orel SG, Schnall MD, Powell CM et al. Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology 196, 115–122 (1995).
  • Kuhl CK, Schrading S, Bieling HB et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 370(9586), 485–492 (2007).
  • Schouten van der Velden AP, Schlooz-Vries MS, Boetes C, Wobbes T. Magnetic resonance imaging of ductal carcinoma in-situ: what is its clinical application? A review. Am. J. Sur. 198(2), 262–269 (2009).
  • Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet 378(9805), 1804–1811 (2011).
  • Pilewskie M, Kennedy C, Shappell C et al. Effect of MRI on the management of ductal carcinoma in situ of the breast. Ann. Surg. Oncol. 20(5), 1522–1529 (2013).
  • Wellings SR, Jensen HM. On the origin and progression of ductal carcinoma in the human breast. J. Natl Cancer Inst. 50, 1111–1118 (1973).
  • Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N. Engl. J. Med. 350, 1430–1441 (2004).
  • Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103, 2481–2484 (2005).
  • Schnitt SJ, Connolly JL, Tavassoli FA et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am. J. Surg. Pathol. 16, 1133–1143 (1992).
  • Mendez I, Andreu FJ, Saez E et al. Ductal carcinoma in situ and atypical ductal hyperplasia of the breast diagnosed at stereotactic core biopsy. Breast J. 7, 14–18 (2001).
  • Renshaw AA, Cartagena N, Schenkman RH, Derhagopian RP, Gould EW. Atypical ductal hyperplasia in breast core needle biopsies. Correlation of size of the lesion, complete removal of the lesion, and the incidence of carcinoma in follow-up biopsies. Am. J. Clin. Pathol. 116(1), 92–96 (2001).
  • Clark J, Warwick R, Carpenter RL, Bowen SW, Duffy, Jones JL. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br. J. Cancer 104(1), 120–127 (2001).
  • Rosen PP. Columnar cell hyperplasia is associated with lobular carcinoma in situ and tubular carcinoma. Am. J. Surg. Pathol. 23(12), 1561 (1999).
  • Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (‘clinging ductal carcinoma in situ’): a simulator of normal mammary epithelium. Cancer 88(9), 2072 (2000).
  • Gundry KR, Berg WA. Treatment issues and core needle breast biopsy: clinical context. AJR Am. J. Roentgenol. 171, 41–49 (1998).
  • Kerlikowske K, Molinaro A, Cha I et al. Characteristics associated with recurrence among women with ductal carcinoma in-situ treated by lumpectomy. J. Nat. Cancer Inst. 95(22), 1692–1702 (2003).
  • Groenewoud JH, Pijnappel RM, van den Akker-Van Marle ME et al. Cost–effectiveness of stereotactic large-core needle biopsy for non-palpable breast lesions compared to open-breast biopsy. Br. J. Cancer 90, 383–392 (2004).
  • Lee CH, Carter D, Philpotts LE et al. Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted? Radiology 217, 466–470 (2000).
  • Schnitt SJ, Collins LC. Biopsy Interpretation of the Breast. Lipincott Williams & Wilkins, PA, USA, 66 (2009).
  • Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional, vacuum-assisted biopsy. Radiology 202, 843–847 (1997).
  • Bijker N, Peterse JL, Duchateau L et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J. Clin. Oncol. 19(8), 2263–2271 (2001).
  • Liberman L, Dershaw DD, Rosen PP et al. Stereotaxic core biopsy of breast carcinoma: accuracy at predicting invasion. Radiology 194, 379–381 (1995).
  • Fisher B, Costantino J, Redmond C et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N. Engl. J. Med. 328(22), 1581–1586 (1993).
  • Hwang ES. The impact of surgery in ductal carcinoma in situ outcomes: the use of mastectomy. J. Natl Cancer Inst. Monogr. 2010(41), 197–199 (2010).
  • Kelley L, Silverstein M, Guerra L. Analyzing the risk of recurrence after mastectomy for DCIS: a new use for the USC/Van Nuys Prognostic Index. Ann. Surg. Oncol. 18(2), 459–462 (2011).
  • Schwartz GF, Solin LJ, Olivotto IA et al. Consensus Conference on the treatment of in situ ductal carcinoma of the breast. April 22–25, 1999. Cancer 88(4), 946–954 (2000).
  • Morrow M, Strom EA, Bassett LW et al. Standard for the management of ductal carcinoma in-situ of the breast (DCIS). CA Cancer J. Clin. 52(5), 256–276 (2002).
  • Winchester PD, Menck HR, Osteen RT et al. Treatment trends for ductal carcinoma in situ of the breast. Ann. Surg. Oncol. 2, 207–213 (1995).
  • Silvertstein MJ, Rosser RJ, Gierson ED et al. Axillary lymph node dissection for intraductal breast carcinoma – is it indicated? Cancer 59, 1819–1824 (1987).
  • Solin LJ, Kurtz J, Fourquet A et al. Fifteen-year results of breast-conserving surgery and definite breast irradiation for the treatment of ductal carcinoma in situ of the breast. J. Clin. Oncol. 14, 754–763 (1996).
  • Fisher B, Land S, Mamounas E et al.. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin. Oncol. 28, 400–418 (2001).
  • Viani GA, Stefano EJ, Afonso SL et al. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiation Oncol. 347, 567–575 (2007).
  • Julien J, Bijker N, Fentiman I et al. Radiotheraphy in breast-conserving treatment for ductal carcinoma Phase III trial 10853. Lancet 355, 528–533 (2000).
  • Wapnir IL, Dignam JJ, Fisher B et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J. Natl Cancer Inst. 103(6), 478–488 (2011).
  • Fisher B, Dignam J, Wolmark N et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J. Clin. Oncol. 16(2), 441–452 (1998).
  • Emdin SO, Granstrand B, Ringberg A et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 45, 536–543 (2006).
  • Holmberg L, Garmo H, Granstrand B et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J. Clin. Oncol. 26(8), 1247–1252 (2008).
  • EORTC Breast Cancer Cooperative Group, EORTC Radiotheapy, Bijker N, Meijnen P, Peterse JL et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organization for Research and Treatment of Cancer randomized Phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J. Clin. Oncol. 24(21), 3381–3387 (2006).
  • Houghton J. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378), 95–102 (2003).
  • McCormick B, Winter K, Hudis C et al. RTOG 9804: a prospective randomized trial for ‘good risk’ ductal carcinoma in situ, comparing radiation to observation. Presented at: ASCO Annual Meeting. 5 June 2012 (Abstract 1004).
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J. Natl Cancer Inst. Monogr. 41, 162–177 (2010).
  • Omlin A, Amichetti M, Azria D et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicenter, retrospective study of the Rare Cancer Network. Lancet Oncol. 7(8), 652–656 (2006).
  • Julian TB, Land SR, Wang Y et al. Is boost therapy necessary in the treatment of DCIS? Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. (Meeting Abstracts) Vol. 26 No. 15S Abstract 537 (2008).
  • Allred DC, Anderson SJ, Paik S et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J. Clin. Oncol. 30(12), 1268–1273 (2012).
  • Silverstein MJ, Lagios MD, Groshen S et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N. Engl. J. Med. 340, 1455–1461 (1999).
  • Wong JS, Kaelin C, Troyan S et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J. Clin. Oncol. 24, 1031–1036 (2006).
  • Hughes LL, Wang M, Page DL et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 27, 5319–5324 (2009).
  • MacAusland SG, Hepel JT, Chong FK et al. An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 110, 2648–2653 (2007).
  • Gilleard O, Goodman A, Cooper M, Davie M, Dunn J. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J. Surg. Oncol. 6, 61 (2008).
  • Silverstein MJ, Lagios MD, Craig PH et al. A prognostic index for ductal carcinoma in situ of breast. Cancer 77, 2267–2274 (1996).
  • Schouten van der Velden AP, Peeters PH, Koot VC, Hennipman A. Local recurrences of ductal carcinoma-in-situ of the breast without radiotherapy: the effect of age. Ann. Surg. Oncol. 13, 990–998 (2006).
  • Rudloff U, Jacks LM, Goldberg JI et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J. Clin. Oncol. 28, 3762–3769 (2010).
  • Yi M, Meric-Bernstam F, Kuerer HM et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J. Clin. Oncol. 30, 600–607 (2012).
  • Solin LJ, Gray R, Goldstein LJ et al. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res. Treat. 134(2), 683–692 (2012).
  • Bidard FC, Vincent-Salomon A, Gomme S et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin. Cancer Res. 14, 3306–3311 (2008).
  • Solin LG, Gray R, Baehner FL et al. A multigene expression to predict local recurrence risk for ductal carcinoma in situ of the breast. J. Natl Cancer Inst. 105(10), 701–710 (2013).
  • Allred DC, Wu Y, Mao S et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin. Cancer Res. 14, 370–378 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.